EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Outcomes of CD19 CAR ‐T therapy in central nervous system lymphoma: Insights from a multicentre experience

Giulio Cassanello iD, Efrat Luttwak iD, Samantha Brown, Sean M Devlin, Brandon Imber, Andrew Ip iD, Lori A Leslie, Noa Golan Accav, Abraham Avigdor, Ronit Marcus, Ofrat Beyar-Katz, Magdalena Corona und 12 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20234 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Giulio Cassanello und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Centre, New York, New York, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Immunotherapy, Adoptive, Antigens, CD19, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Associazione italiana contro le leucemie-linfomi e mieloma Milano e Provincia ONLUS, Fundación Alfonso Martin Escudero.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell therapy has reshaped the treatment paradigm for relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). However, its role in central nervous system lymphoma (CNSL) remains uncertain. We conducted a multicentre, retrospective study on 54 adult R/R CNSL patients treated at four international institutions with commercial (axi‐cel, tisa‐cel, liso‐cel) or a point of care (POC) CD19‐CAR T‐cell products. At day 100 post CAR‐T infusion, 65% of patients attained a complete response as their best response in both systemic and central nervous system compartments. The median progression‐free survival (PFS) was 7.5 months, with a 1‐year PFS of 35%. The median overall survival (OS) was 19 months, with a 1‐year OS of 63%. In multivariable analyses, CAR‐T product was significantly associated with PFS ( p = 0.009) and OS ( p = 0.013), with patients receiving tisa‐cel exhibiting poorer outcomes than axi‐cel and patients receiving liso‐cel or POC CAR‐T product demonstrating better outcomes than axi‐cel. Toxicity profiles were consistent with pivotal trials in R/R DLBCL. Grade ≥3 cytokine release syndrome occurred in 11% of patients, while grade ≥3 immune‐effector cell‐associated neurotoxicity syndrome was observed in 28%. Our study supports the feasibility and safety of anti‐CD19 CAR‐T therapy in CNSL. The specific CAR‐T product infused emerged as a factor influencing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsImmunotherapy, AdoptiveAntigens, CD19Receptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesAged, 80 and overTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

cellular therapieshaematological oncologyimmunotherapylymphoma

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Centre, New York, New York, USA.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Centre, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Centre, New York, New York, USA.
  • Department of Radio-Oncology, Memorial Sloan Kettering Cancer Centre, New York, New York, USA.
  • Hackensack University Medical Centre, Hackensack, New Jersey, USA.

ORCID-Profile: Giulio Cassanello, Efrat Luttwak, Andrew Ip, Miguel-Angel Perales, Roni Shouval

Förderung

  • NCI NIH HHS
  • Associazione italiana contro le leucemie-linfomi e mieloma Milano e Provincia ONLUS
  • Fundación Alfonso Martin Escudero

Zitieren

APA

Cassanello, G., Luttwak, E., Brown, S., Devlin, S. M., Imber, B., Ip, A., Leslie, L. A., Accav, N. G., Avigdor, A., Marcus, R., Beyar-Katz, O., Corona, M., Luna De Abia, A., Calabrese De Feo, J., Rivas Delgado, A., Lue, J. K., Grommes, C., Shah, G. L., Park, J., …, & Palomba, M. L. (2025). Outcomes of CD19 CAR ‐T therapy in central nervous system lymphoma: Insights from a multicentre experience. British Journal of Haematology. https://doi.org/10.1111/bjh.20234

Vancouver

Cassanello G, Luttwak E, Brown S, Devlin SM, Imber B, Ip A, et al. Outcomes of CD19 CAR ‐T therapy in central nervous system lymphoma: Insights from a multicentre experience. British Journal of Haematology. 2025. doi:10.1111/bjh.20234

BibTeX
@article{Cassanello2025,
  author = {Cassanello, Giulio and Luttwak, Efrat and Brown, Samantha and Devlin, Sean M and Imber, Brandon and Ip, Andrew and Leslie, Lori A and Accav, Noa Golan and Avigdor, Abraham and Marcus, Ronit and Beyar-Katz, Ofrat and Corona, Magdalena and Luna De Abia, Alejandro and Calabrese De Feo, Jacopo and Rivas Delgado, Alfredo and Lue, Jennifer K and Grommes, Christian and Shah, Gunjan L and Park, Jae and Perales, Miguel-Angel and Salles, Gilles and Shouval, Roni and Scordo, Michael and Palomba, M Lia},
  title = {Outcomes of CD19 CAR ‐T therapy in central nervous system lymphoma: Insights from a multicentre experience},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20234}
}
Kostenlos starten →